Ideaya’s uveal melanoma drug exceeds success benchmark in late-stage trial
Ideaya公司葡萄膜黑色素瘤药物在后期试验中超出成功基准

Ideaya’s late-stage data for a rare eye cancer drug has passed the company’s benchmark for success, bolstering expectations for a planned accelerated filing in the US.
Ideaya一款用于治疗罕见眼部肿瘤的候选药物在后期研究中达到了公司设定的成功基准，提振了外界对其在美国计划申请加速审批的预期。